journal article·2015Open access

Theranostic etoposide phosphate/indium nanoparticles for cancer therapy and imaging

Ramishetti Srinivas, Andrew Satterlee, Yuhua Wang, Yuan Zhang, Yongjun Wang, Leaf Huang

Nanoscale· Volume 7· Issue 44

Abstract

Etoposide phosphate (EP), a water-soluble anticancer prodrug, is widely used for treatment of many cancers. After administration it is rapidly converted to etoposide, its parent compound, which exhibits anticancer activity. Difficulty in parenteral administration necessitates the development of a suitable nanoparticle delivery system for EP. Here we have used indium both as a carrier to deliver etoposide phosphate to tumor cells and as a SPECT imaging agent through incorporation of (111)In. Etoposide phosphate was successfully encapsulated together with indium in nanoparticles, and exhibited dose dependent cytotoxicity and induction of apoptosis in cultured H460 cancer cells via G2/M cell cycle arrest. In a mouse xenograft lung cancer model, etoposide phosphate/indium nanoparticles induce tumor cell apoptosis, leading to significant enhancement of tumor growth inhibition compared to the free drug.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery

Eshelman School of Pharmacy

University of North Carolina at Chapel Hill

Chapel Hill, USA

UNC and NCSU Joint Department of Biomedical Engineering

References (29)

Show source-provided references
1. Hande · Eur. J. Cancer · 1998 · 34 · 151410.1016/S0959-8049(98)00228-7 ↗
2. Larsen · Prog. Cell Cycle Res. · 1996 · 2 · 22910.1007/978-1-4615-5873-6_22 ↗
3. Fields · Clin. Cancer Res. · 1995 · 1 · 105
4. Rose · Invest. New Drugs · 1990 · 8 · S2510.1007/BF00171981 ↗
5. Senter · Proc. Natl. Acad. Sci. U. S. A. · 1988 · 85 · 484210.1073/pnas.85.13.4842 ↗
6. Heath · Annu. Rev. Med. · 2008 · 59 · 25110.1146/annurev.med.59.061506.185523 ↗
7. Torchilin · Nat. Rev. Drug Discovery · 2014 · 13 · 81310.1038/nrd4333 ↗
8. Fang · Adv. Drug Delivery Rev. · 2011 · 63 · 13610.1016/j.addr.2010.04.009 ↗
9. Ramishetti · Ther. Delivery · 2012 · 3 · 142910.4155/tde.12.127 ↗
10. Chen · Nanotechnology · 2012 · 23 · 04510410.1088/0957-4484/23/4/045104 ↗
11. Qian · Int. J. Nanomed. · 2012 · 7 · 5781
12. Lamprecht · J. Controlled Release · 2006 · 112 · 20810.1016/j.jconrel.2006.02.014 ↗
13. Kalhapure · Colloids Surf., B · 2013 · 105 · 21510.1016/j.colsurfb.2013.01.011 ↗
14. Callewaert · J. Biomed. Mater. Res., Part A · 2013 · 101 · 131910.1002/jbm.a.34442 ↗
15. Snehalatha · Drug Delivery · 2008 · 15 · 27710.1080/10717540802006500 ↗
16. Shah · J. Appl. Polym. Sci. · 2013 · 127 · 499110.1002/app.38107 ↗
17. Tang · Biomaterials · 2010 · 31 · 33910.1016/j.biomaterials.2009.09.033 ↗
18. Psimadas · J. Pharm. Sci. · 2012 · 101 · 227110.1002/jps.23146 ↗
19. Kelkar · Bioconjugate Chem. · 2011 · 22 · 187910.1021/bc200151q ↗
20. Kairemo · Eur. J. Nucl. Med. · 1996 · 23 · 63110.1007/BF00834524 ↗
21. Kairemo · J. Nucl. Biol. Med. · 1994 · 38 · 135
22. Zhang · Biomaterials · 2013 · 34 · 344710.1016/j.biomaterials.2013.01.063 ↗
23. Sleiman · Clin. Cancer Res. · 2000 · 6 · 3756
24. Chaitanya · Cell Commun. Signaling · 2010 · 8 · 3110.1186/1478-811X-8-31 ↗
25. Smith · Br. J. Cancer · 1994 · 70 · 91410.1038/bjc.1994.420 ↗
26. Satterlee · J. Controlled Release · 2015 · 217 · 17010.1016/j.jconrel.2015.08.048 ↗
27. Witterland · Pharm. World Sci. · 1996 · 18 · 16310.1007/BF00820727 ↗
28. Beijnen · Int. J. Pharm. · 1988 · 41 · 16910.1016/0378-5173(88)90149-4 ↗
29. Karl · Appl. Environ. Microbiol. · 1980 · 40 · 54910.1128/AEM.40.3.549-561.1980 ↗